Strontium  	Strontium  	 FW	B-NP
ranelate  	ranelate  	 FW	I-NP
in  	in  	 FW	O
post-menopausal  	post-menopausal  	 FW	B-NP
osteoporosis  	osteoporosis  	 FW	I-NP
Strontium  	Strontium  	 FW	I-NP
ranelate  	ranelate  	 FW	I-NP
is  	is  	 VBZ	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
first-line  	first-line  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
with  	with  	 IN	O
proven  	proven  	 JJ	O
anti-fracture  	anti-fracture  	 JJ	B-NP
activity  	activity  	 NN	I-NP
used  	used  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
therapy  	therapy  	 NN	O
of  	of  	 IN	O
post-menopausal  	post-menopausal  	 JJ	B-NP
osteoporosis 	osteoporosis 	 NN	I-NP
.  	.  	 .	O
Its  	Its  	 PRP$	O
mechanism  	mechanism  	 NN	O
of  	of  	 IN	O
action  	action  	 NN	O
makes  	makes  	 VBZ	O
it 	it 	 PRP	O
,  	,  	 ,	O
however 	however 	 RB	O
,  	,  	 ,	O
different  	different  	 JJ	O
from  	from  	 IN	O
other  	other  	 JJ	O
drugs 	drugs 	 NNS	O
,  	,  	 ,	O
since  	since  	 IN	O
it  	it  	 PRP	O
simultaneously  	simultaneously  	 RB	O
stimulates  	stimulates  	 CD	O
two  	two  	 CD	O
reverse  	reverse  	 JJ	B-NP
processes 	processes 	 NNS	I-NP
:  	:  	 :	O
bone  	bone  	 JJ	O
formation  	formation  	 NN	O
and  	and  	 CC	O
bone  	bone  	 NN	B-NP
resorption 	resorption 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
action  	action  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
agent  	agent  	 NN	B-NP
depends  	depends  	 VBZ	O
on  	on  	 IN	O
various  	various  	 JJ	O
mechanisms 	mechanisms 	 NNS	O
,  	,  	 ,	O
including  	including  	 VBG	O
the  	the  	 DT	O
activation  	activation  	 NN	B-NP
of  	of  	 IN	I-NP
calcium  	calcium  	 JJ	I-NP
receptors 	receptors 	 NNS	I-NP
,  	,  	 ,	O
localised  	localised  	 VBG	O
on  	on  	 IN	O
osteoblasts  	osteoblasts  	 NN	B-NP
and  	and  	 CC	O
osteoclasts 	osteoclasts 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
on  	on  	 IN	O
the  	the  	 DT	O
influence  	influence  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
OPG 	OPG 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
RANKL  	RANKL  	 NNP	I-NP
system 	system 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
drug  	drug  	 NN	O
effectively  	effectively  	 RB	O
prevents  	prevents  	 VBZ	O
spinal 	spinal 	 JJ	B-NP
,  	,  	 ,	O
hip  	hip  	 NN	B-NP
and  	and  	 CC	O
extravertebral  	extravertebral  	 JJ	B-NP
fractures 	fractures 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
agent 	agent 	 NN	O
's  	's  	 POS	O
anti-fracture  	anti-fracture  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
within  	within  	 IN	O
the  	the  	 DT	O
spine  	spine  	 NN	B-NP
does  	does  	 VBZ	O
not  	not  	 RB	O
depend  	depend  	 VB	O
on  	on  	 IN	O
the  	the  	 DT	O
patient 	patient 	 NN	O
's  	's  	 POS	O
age 	age 	 NN	O
,  	,  	 ,	O
or  	or  	 CC	O
on  	on  	 IN	O
base  	base  	 NN	B-NP
BMD  	BMD  	 NN	I-NP
values 	values 	 NNS	I-NP
,  	,  	 ,	O
or  	or  	 CC	O
on  	on  	 IN	O
the  	the  	 DT	O
concentration  	concentration  	 NN	B-NP
of  	of  	 IN	O
bone  	bone  	 NN	O
metabolism  	metabolism  	 NN	O
markers 	markers 	 NN	O
.  	.  	 .	O
As  	As  	 RB	O
to  	to  	 TO	O
the  	the  	 DT	O
anti-fracture  	anti-fracture  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
hip 	hip 	 NN	B-NP
,  	,  	 ,	O
it  	it  	 PRP	O
concerns  	concerns  	 VBZ	O
women  	women  	 NNS	O
with  	with  	 IN	O
an  	an  	 DT	O
increased  	increased  	 JJ	O
bone  	bone  	 NN	O
fracture  	fracture  	 NN	O
risk 	risk 	 NN	O
.  	.  	 .	O
Strontium  	Strontium  	 JJ	O
ranelate  	ranelate  	 JJ	B-NP
increases  	increases  	 NNS	I-NP
bone  	bone  	 NN	O
mineral  	mineral  	 NN	O
density  	density  	 NN	O
within  	within  	 IN	O
the  	the  	 DT	O
lumbar  	lumbar  	 JJ	O
spine  	spine  	 NN	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
hip 	hip 	 NN	B-NP
,  	,  	 ,	O
decreases  	decreases  	 VBZ	O
the  	the  	 DT	O
concentrations  	concentrations  	 NNS	B-NP
of  	of  	 IN	O
bone  	bone  	 JJ	O
resorption  	resorption  	 JJ	B-NP
markers 	markers 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
increases  	increases  	 VBZ	O
the  	the  	 DT	O
concentrations  	concentrations  	 NNS	B-NP
of  	of  	 IN	O
bone  	bone  	 NN	O
formation  	formation  	 NN	O
markers 	markers 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
drug  	drug  	 NN	O
is  	is  	 VBZ	O
administered  	administered  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
daily  	daily  	 JJ	O
2.0  	2.0  	 CD	O
g  	g  	 CD	B-NP
oral  	oral  	 JJ	I-NP
dose 	dose 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
indications  	indications  	 NNS	O
to  	to  	 TO	O
therapy  	therapy  	 NN	O
with  	with  	 IN	O
strontium  	strontium  	 JJ	B-NP
ranelate 	ranelate 	 NN	I-NP
,  	,  	 ,	O
specifying  	specifying  	 VBG	O
also  	also  	 RB	O
its  	its  	 PRP$	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
and  	and  	 CC	O
contraindications 	contraindications 	 NN	B-NP
.  	.  	 .	O
We  	We  	 PRP	O
compare  	compare  	 VBP	O
the  	the  	 DT	O
anti-fracture  	anti-fracture  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
of  	of  	 IN	I-NP
strontium  	strontium  	 JJ	I-NP
ranelate  	ranelate  	 NN	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
other  	other  	 JJ	O
agents  	agents  	 NNS	O
of  	of  	 IN	O
proven  	proven  	 JJ	O
anti-fracture  	anti-fracture  	 JJ	B-NP
activity 	activity 	 NN	I-NP
,  	,  	 ,	O
based  	based  	 VBN	O
on  	on  	 IN	O
published  	published  	 VBN	O
clinical  	clinical  	 JJ	B-NP
studies 	studies 	 NNS	I-NP
.  	.  	 .	O
